GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Online-Ressource
    Online-Ressource
    Japanese College of Surgeons ; 2014
    In:  Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) Vol. 39, No. 5 ( 2014), p. 954-958
    In: Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), Japanese College of Surgeons, Vol. 39, No. 5 ( 2014), p. 954-958
    Materialart: Online-Ressource
    ISSN: 0385-7883 , 1882-9112
    Originaltitel: 虫垂炎にて発症したアメーバ性大腸炎の1例
    Sprache: Englisch , Japanisch
    Verlag: Japanese College of Surgeons
    Publikationsdatum: 2014
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    Japan Gastrointestinal Endoscopy Society ; 2014
    In:  Progress of Digestive Endoscopy Vol. 84, No. 1 ( 2014), p. 94-95
    In: Progress of Digestive Endoscopy, Japan Gastrointestinal Endoscopy Society, Vol. 84, No. 1 ( 2014), p. 94-95
    Materialart: Online-Ressource
    ISSN: 1348-9844 , 2187-4999
    Sprache: Englisch
    Verlag: Japan Gastrointestinal Endoscopy Society
    Publikationsdatum: 2014
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    In: BMC Cancer, Springer Science and Business Media LLC, Vol. 14, No. 1 ( 2014-12)
    Kurzfassung: Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable early-stage breast cancer. It would be advantageous to determine the chemosensitivity of tumors before initiating NAC. One of the parameters potentially compromising such chemosensitivity would be a hypoxic microenvironment of cancer cells. The aim of this study was thus to clarify the correlation between expression of the hypoxic marker carbonic anhydrase-9 (CA9) and chemosensitivity to NAC as well as prognosis of breast cancer patients. Methods A total of 102 patients with resectable early-stage breast cancer was treated with NAC consisting of FEC (5-fluorouracil, epirubicin, and cyclophosphamide) followed by weekly paclitaxel before surgery. Core needle biopsy (CNB) specimens and resected tumors were obtained from all patients before and after NAC, respectively. Chemosensitivity to NAC and the prognostic potential of CA9 expression were evaluated by immunohistochemistry. Results CA9 positivity was detected in the CNB specimens from 47 (46%) of 102 patients. The CA9 expression in CNB specimens was significantly correlated with pathological response, lymph node metastasis, and lymph-vascular invasion. Multivariate analysis revealed that the CA9 expression in CNB specimens was an independent predictive factor for pathological response. The Kaplan-Meier survival curve revealed a significant negative correlation (p = 0.013) between the disease-free survival (DFS) and the CA 9 expression in resected tissues after NAC. Multivariate regression analyses indicated that the CA9 expression in resected tissues was an independent prognostic factor for DFS. Conclusions CA9 expression in CNB specimens is a useful marker for predicting chemosensitivity, and CA9 expression in resected tissue is prognostic of DFS in patients with resectable early-stage breast cancer treated by sequential FEC and weekly paclitaxel prior to resection.
    Materialart: Online-Ressource
    ISSN: 1471-2407
    Sprache: Englisch
    Verlag: Springer Science and Business Media LLC
    Publikationsdatum: 2014
    ZDB Id: 2041352-X
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    In: Oncology Letters, Spandidos Publications, Vol. 7, No. 3 ( 2014-3), p. 663-668
    Materialart: Online-Ressource
    ISSN: 1792-1074 , 1792-1082
    Sprache: Englisch
    Verlag: Spandidos Publications
    Publikationsdatum: 2014
    ZDB Id: 2573196-8
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 2265-2265
    Kurzfassung: Introduction: HER3 (erbB-3) is a member of the epidermal growth factor receptor (EGFR) family. After dimerization with other members of the EGFR family several signal transduction cascades can be activated.HER2/HER3 heterodimer is likely to be the most effective complex for activating downstream pathways.Because of special importance of HER2/HER3 heterodimer in tumorgenesis, the signaling pathways and downstream effectors of the HER family become key molecules in the strategy of cancer therapy.HER3 is overexpressed in diverse human cancers, and has been associated with poor prognosis in breast, lung, and ovarian cancer.The objective of this study was to evaluate the significance of HER3 expression in pancreatic cancer cells. Material and Methods: A total 86 patients were enrolled.The pancreatic cancers were stained with antibodies against HER3 by immunohistochemistry. HER3 expression was evaluated by intensity of staining.Intensity was given scores 0-3 (score 0:no staining, score1+:barely perceptible staining, score2+:moderate staining, score3+:strong staining). Scores of 0 and 1+ were considered to be negative for HER3 expression, while 2+ and 3+ were considered to be positive (overexpression).We examined the association between HER3 expression and other clinicopathologic variables. Results: HER3 expression was positive in 36 (41.9%) cases.There were no significant correlation between HER3 expression and other clinicopathological factors. The prognosis of HER3 positive patients was significantly poorer than that of HER3-negative patients (p=0.002). A univariate survival analysis revealed that HER3 overexpression, intrapancreatic nerve invasion and T category were significantly correlated with patient survival. A multivariate analysis showed HER3 overexpression was an independent predictor of worse prognosis in resectable pancreatic cancer. Conclusion: The expression of HER3 might be a novel predictive prognostic marker for patients with pancreatic cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2265. doi:10.1158/1538-7445.AM2011-2265
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2011
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4054-4054
    Kurzfassung: Background: Various types of solid tumors, including gastric cancer, have a heterogeneously hypoxic environment which has been currently considered to be associated with aggressive tumor phenotypes cancer. Stromal cell-derived factor (SDF)-1 and C-X-C chemokine receptor type 4 (CXCR-4) form an important chemokine/receptor pair, and are supposed to be up-regulated by hypoxia inducible factor-1 (HIF-1). Although the chemokine signaling is associated with malignant potential of various carcinomas, few studies have addressed the expression and function of CXCR4 and SDF-1 under hypoxia in gastric cancer. The aim of our study was to clarify the significance of CXCR4 and SDF-1 under hypoxia in gastric carcinoma by evaluating the expression of a hypoxic marker, a carbonic anhydrase 9 (CA-9). Experimental Design: A total of 297 patients who had undergone a resection of the primary tumor and were confirmed histologically to have sporadic gastric cancer were enrolled in this study. Expressions of CXCR4, SDF-1, and CA-9, were assessed by immunohistochemistry. We examined the association between the expression levels of CXCR4, SDF-1, and CA-9 and clinicopathologic variables of patients with gastric cancers. Furthermore, using three diffuse-type gastric cancer cell lines, OCUM-2M, OCUM-2MD3, and OCUM-12, expression level of CXCR4 and SDF-1 in hypoxia (1% O2) were examined by RT-PCR. Results: CA-9 expression was found in 48% (143/297) of gastric cancers, CXCR4 was 47% (141/297), and SDF-1 was 41% (122/297). The CA9 expression was significantly correlated with CXCR4 expression and SDF-1. The CA9 expression level was significantly high in cases diffuse-type carcinoma (p=0.028). The prognosis for CA-9-positive patients was significantly poorer than that of CA-9-negative patients (p & lt;0.001,log-rank). The CXCR4 expression level was significantly correlated with lymph node metastasis (p & lt;0.001), and with higher stages (p & lt;0.001). The SDF-1 expression level was significantly higher with lymph node metastasis(p & lt;0.001), and with higher stages (p & lt;0.001). The prognosis for CXCR4-positive patients was significantly poorer than that of CXCR4-negative patients (p & lt;0.001, log-rank). The prognosis for SDF-1-positive patients was significantly poorer than that of SDF-1-negative patients (p=0.008, log-rank). The expression level of CXCR4 mRNA was significantly increased by hypoxia, in comparison with that in normoxia in all of gastric cancer cells. Conclusion: CXCR4/SDF-1 expression of gastric cancer cells might be regulated with by hypoxic condition. CXCR4/SDF-1 axis might play an important role for the progression of diffuse-type gastric carcinoma with hypoxic environment. Citation Format: Haruhito Kinoshita, Masakazu Yashiro, Tamami Morisaki, Tatsunari Fukuoka, Tsuyoshi Hasegawa, Toshiki Hirakawa, Naoki Aomatsu, Katsunobu Sakurai, Kenjiro Kimura, Hisashi Nagahara, Takahiro Toyokawa, Ryosuke Amano, Eiji Noda, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Hiroshi Otani, Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa. Significance of CXCR4/SDF-1 axis expression in gastric cancer under hypoxic enviroment. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4054. doi:10.1158/1538-7445.AM2013-4054
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2013
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 7
    Online-Ressource
    Online-Ressource
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 8_Supplement ( 2011-04-15), p. 3137-3137
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 3137-3137
    Kurzfassung: Background: Current studies have demonstrated that neoadjuvant chemotherapy (NAC) improves the prognosis of patients with breast cancer, however, no reliable maker to predict chemosensitivity of NAC is not available. Although E-cadherin is one of the markers for chemosensitivity in several types of carcinomas, the significance of E-cadherin for chemosensitivity of NAC remains unclear. The aim of this study was to evaluate the value of E-cadherin as a surrogate maker of NAC for breast cancer. Experimental Design: A total of 104 patients with breast cancer of stage II and III, as evaluated by core needle biopsy and ultrasonography, was treated with NAC, including FEC (5-fluorouracil + epirubicin + cyclophosphamide) followed by weekly paclitaxel. Expressions of E-cadherin, estrogen receptor, progesterone receptor, and HER2 were assessed by immunohistochemistry. Clinical responses and pathological responses were classified according to WHO criteria or The General Rules for Breast Cancer. Results: A clinical response (responder; complete response + partial response) was observed in 93 (89%) of 104 patients. The pathological complete response rate (pCR) was 29% (30/104). E-cadherin was positive in 60 (57%) of 104 breast cancer. Fifty-eight (96%) of 60 E-cadherin-positive tumors were responders, while 35 (80%) of 44 E-cadherin-negative tumors were non-responders (p=0.005). The pCR rate (37%; 22/60) of E-cadherin-positive tumors also was significantly (p=0.04) higher than that (18%; 8/44) of E-cadherin-negative tumors. Among the 104 breast cancer cases, 32 (31%) revealed a triple-negative phenotype (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative). The pCR of triple-negative breast cancer was 34% (11/32). In the 32 triple-negative breast cancers, the pCR rate (64%; 7/11) of E-cadherin-positive tumors was significantly (p=0.004) higher than that (19%; 4/21) of E-cadherin-negative tumors.Conclusion: E-cadherin might be a clinically useful maker to predicting the response to NAC in breast cancer, especially in triple-negative breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3137. doi:10.1158/1538-7445.AM2011-3137
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2011
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 708-708
    Kurzfassung: Introduction: Insulin like growth factor 1 receptor (IGF1R) reported to be overexpressed in some types of human carcinomas, including lung cancer, and breast cancer. However no report of the significance of IGF1R expression was available in pancreatic cancer. Most patients with pancreatic cancer die within 2 years at diagnosis even after curative resection. The objective of this study was to evaluate the significance of IGF1R expression in human pancreatic cancer. Material and Methods: A total 122 patients with pancreatic cancer was studied. Paraffin embedded species of pancreatic cancers were stained with antibodies against IGF1R. IGF1R expression was evaluated by intensity of staining. Semi-quantitative scores of zero (no staining), 1+ (weak staining), 2+ (moderate staining), or 3+ (strong staining) were assigned to each sample based on the intensity of staining. Scores of 2+ or 3+ were defined as IGF1R-positive staining. The association between IGF1R expression and clinicopathologic variables was examined. Results: IGF1R expression was positive in 50 (40.1%) of 122 cases. Kaplan-Meier analysis demonstrated the prognosis of IGF1R-positive patients was significantly (p=0.0076) poorer than that of IGF1R-negative, and median survival time of patients with IGF1R-positive was 37.3 months, while that of patients with IGF1R-negative samples was 60.8 months. There were no associations between IGF1R overexpression and clinicopathological factors, including tumor location, tumor size, tumor differentiation, and T/N categories according to the International Union against Cancer. Multivariate analysis showed IGF1R expression and lymph node metastasis were independent predictors of worse prognosis in pancreatic cancer. Conclusion: The expression of IGF1R might be a novel predictive prognostic marker for patients with pancreatic cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 708. doi:1538-7445.AM2012-708
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2012
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 9
    Online-Ressource
    Online-Ressource
    The Japanese Journal of Gastroenterological Surgery ; 2011
    In:  The Japanese Journal of Gastroenterological Surgery Vol. 44, No. 1 ( 2011), p. 57-63
    In: The Japanese Journal of Gastroenterological Surgery, The Japanese Journal of Gastroenterological Surgery, Vol. 44, No. 1 ( 2011), p. 57-63
    Materialart: Online-Ressource
    ISSN: 0386-9768 , 1348-9372
    Sprache: Unbekannt
    Verlag: The Japanese Journal of Gastroenterological Surgery
    Publikationsdatum: 2011
    ZDB Id: 2303686-2
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3995-3995
    Kurzfassung: Introduction: Prostaglandin D2 (PGD2) has been demonstrated to have not only physiological responses but also anti-tumor effects against some types of cancer cells such as a lung cancer. PGD2 act through two major receptors, DP1 and DP2 of chemoattractant receptor-like molecule on the Th2 cell. Recently, some papers reported that PGD2 may act through PPARγ, suggesting that the effects of PGD2 are involved in either PGD2 dependent or independent pathway. PGD2 metabolite, 15-deoxy-Δ12 14-PGJ2, activates peroxisome proliferator-activated receptor γ (PPARγ) which induces growth inhibition of various cells. PPARγ is expressed in various types of cancers including gastric cancer. Since the role of PGD2 on gastric cancer cells is still unknown, this study is aimed to investigate the effect of PGD2 signalings on the proliferation of gastric cancer cells. Materials and Methods: Three human gastric cancer cell lines, OCUM-2M, OCUM-12, and MKN-74, were used. Effect of PGD2 or PPARγ antagonist on the proliferation of cancer cells was examined by MTT assay. The expression level of PGD2 receptor, DP1 and DP2, and PPARγ of gastric cancer cells was examined by RT-PCR. The effect of PGD2 on cell cycle was examined with PI staining by flowcytometry. Results: PGD2 significantly decreased the proliferation of OCUM-2M and MKN-74 cells at a dose-dependent manner, but not that of OCUM-12. PGD2 receptors, DP1 and DP2, were not expressed in 3 gastric cancer cell lines while PPARγ was expressed in OCUM-2M and MKN-74. BADGE, a PPARγ antagonist, significantly suppressed the growth-inhibitory effects of PGD2 on OCUM-2M and MKN-74 cells. PGD2 increased G0/G1 phase of cancer and decereased G2/M phase. Conclusion: PGD2 decreased the proliferation of gastric cancer cells through PPARγ dependent pathway. PGD2 might be a promising therapeutic agent for gastric cancer with PPARγ expression. Citation Format: Tatsunari Fukuoka, Masakazu Yashiro, Hiroshi Takeda, Takayuki Maruyama, Haruhito Kinoshita, Tamammi Morisaki, Tsuyoshi Hasegawa, Toshiki Hirakawa, Naoki Aomatsu, Katsunobu Sakurai, Kenjiro Kimura, Hisashi Nagahara, Takahiro Toyokawa, Ryosuke Amano, Eiji Noda, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Hiroshi Otani, Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa. Antitumor effect of prostaglandin D2 by peroxisome proliferator-activated receptor gamma (PPARγ)-dependent pathway in gastric carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3995. doi:10.1158/1538-7445.AM2013-3995
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2013
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...